Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2386-2393

  Hanahan, D ^a   Christofori, G ^b   Naik, P ^c   Arbeit, J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; MINOCYCLINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CARCINOGENESIS; GENE EXPRESSION; GENETIC ENGINEERING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

EID: 0030512608     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00401-7     Document Type: Article

References (44)

1. 1. Hanahan D. Dissecting multistep tumorigenesis in transgenic mice. Annu Rev Genet 1988, 22, 479-519.
2. 2. Hanahan D. Transgenic mice as probes into complex systems. Science 1989, 246, 1265-1275.
3. 3. Adams JM, Cory S. Transgenic models of tumor development. Science 1991, 254, 1161-1167.
4. 4. Frost P, Hart I, Kerbel RS. Cancer and metastasis reviews -transgenic mice. Cancer Metast Rev 1995, 14, 77-161.
5. 5. Hanahan D. Heritable formation of pancreatic β-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315, 115-121.
6. 6. Lacey M, Alpert S, Hanahan D. The bovine papillomavirus genome elicits skin tumours in transgenic mice. Nature 1986, 322, 609-612.
7. 7. Arbeit J, Munger K, Howley P, Hanahan D. Progressive squamous epithelial neoplasia in K14-HPV16 transgenic mice. J Virol 1994, 68, 4358-4368.
8. 8. Coussens LM, Hanahan D, Arbeit J. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol, in press.
9. 9. Teitelman G, Alpert S, Hanahan D. Proliferation, senescence and neoplastic progression of β cells in hyperplastic pancreatic islets. Cell 1988, 52, 97-105.
10. 10. Christofori G, Naik P, Hanahan D. Insulin-like growth factor II is focally up-regulated and functionally involved as a co-factor in oncogene induced tumorigenesis. Nature 1994, 369, 414-418.
11. 11. Christofori G, Naik P, Hanahan D. Deregulation of both imprinted and expressed alleles of the IGF-II gene during β-cell tumorigenesis. Nature Genet 1995a, 10, 196-201.
12. 12. Naik PN, Karrim J, Hanahan D. Variation in apoptosis during multi-stage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes & Dev, 1996, 13, 1847-1857.
13. 13. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339, 58-61.
14. 14. Sippola-Thiele M, Hanahan D, Howley PM. Cell heritable stages of tumor progression in transgenic mice harboring the bovine papillomavirus type 1 genome. Mol Cell Biol 1988, 9, 925-934.
15. 15. Bossy-Wetzel E, Bravo R, Hanahan D. Transcription factors JunB and c-Jun are selectively up-regulated and functionally implicated in fibrosarcoma development. Genes & Dev 1992, 6, 2340-2351.
16. 16. Kandel J, Bossy-Wetzel E, Radvany F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66, 1095-1104.
17. 17. Hurlin PJ, Foley KP, Aver D, Eisenman RN, Hanahan D, Arbeit JM. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene 1995, 11, 2487-2501.
18. 18. Arbeit JM. Transgenic models of epidermal neoplasia and multi-stage carcinogenesis. Cancer Surveys 1996, 26, 7-34.
19. 19. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs 1995b, 6, 3-18.
20. 20. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
21. 21. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992, 267, 10931-10934.
22. 22. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal. FASEB J 1995, 9, 919-925.
23. 23. Bouck N, Stellmach V, Hsu S. How tumors become angiogenic. Adv Cancer Res, in press.
24. 24. Christofori G. The role of fibroblast growth factors in tumour progression and angiogenesis. In Bicknell R, Lewis CE, Ferrara N, eds. Tumour Angiogenesis. Oxford, Oxford University Press, in press.
25. 25. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak H. Control of Angiogenesis. Berlin, Birkhauser Verlag, 1996.
26. 26. Arbeit JM, Olson D, Hanahan D. Upregulation of fibroblast growth factors and their receptors during multistage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene 1996, 13, 1847-1857.
27. 27. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995, 9, 1760-1770.
28. 28. Oloffsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996, 93, 2576-2581.
29. 29. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15, 290-298.
30. 30. Lee J, Gray A, Yuan J, Luoh S-M, Avraham H, Wood WI. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 1996, 93, 1988-1992.
31. 31. Grimmond S, Lagercrantz J, Drinkwater C, et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res 1996, 6, 124-131.
32. 32. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995, 108, 2369-2379.
33. 33. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
34. 34. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995, 92, 768-772.
35. 35. Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995, 15, 5363-5368.
36. 36. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995a, 55, 4575-4580.
37. 37. Folkman J. Tumor angiogenesis. In Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, W.B. Saunders Company, 1995, 206-232.
38. 38. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333, 1757-1763.
39. 39. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265, 1582-1584.
40. 40. Parangi S, Dietrich W, Christofori G, Lander E, Hanahan D. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic mouse model of islet cell carcinoma. Cancer Res 1995, 55, 6071-6076.
41. 41. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996, 93, 2002-2007.
42. 42. Boone CW, Kelloff GJ. Intraepithelial neoplasia, surrogate endpoint biomarkers and cancer chemoprevention. J Cell Biochem 1993, 17F (Suppl.), 37-48.
43. 43. Arbeit J, Howley P, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in HPV16 transgenic mice. Proc Natl Acad Sci USA 1996, 93, 2903-2935.
44. 44. Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK. Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 1996, 149, 59-71.